Man dies after being sucked into MRI machine by his own metal necklace
A man who was violently sucked into an MRI machine by a metal chain around his neck has died, police in New York said.
The man was wearing a large metallic chain around his neck, which caused him to be drawn into the machine, the Nassau County Police Department said in a news release. The incident took place at the Nassau Open MRI medical facility in the village of Westbury on the North Shore of Long Island.
Police responded to the facility just after 4:30 p.m. on July 16. At the scene, witnesses told officers a 61-year-old man "entered an unauthorized M.R.I. room while the scan was in progress," police said.
Multiple injuries in incident: Over 2 dozen people injured after vehicle crashes into crowd in Los Angeles
He was transported to a local hospital where he was initially listed in critical condition. He died at the hospital on July 17 at 2:36 p.m., police said.
Officials have not yet released the name of the man nor whether he was a visitor to the facility, a patient or if he worked there. Police did not elaborate on the type or extent of the man's injuries.
Man drawn into MRI from 'a large metallic chain around his neck'
According to police, the machine's magnetic field immediately attracted "a large metallic chain" the victim wore, which quickly pulled him into the machine and "resulted in a medical episode."
The investigation into the incident is ongoing, police said.
USA TODAY contacted Nassau Open MRI on July 18 but has not received a response.
MRI risks may include 'injuries from projectiles'
Magnetic resonance imaging, or MRI, is a non-invasive 3D imaging technology used to examine patients' organs, tissues and skeletal system for diagnostic purposes, according to the Mayo Clinic.
Adverse events from MRI scans "are rare," according to the U.S. Food and Drug Administration (FDA), which regulates MRI equipment.
Millions of MRI scans are performed across the nation every year, the FDA wrote on its website. The agency said it receives around 300 incident reports annually involving MRI scanners and coils from manufacturers, distributors, user facilities and patients.
Most of the reports, according to the FDA, include burns, as well as injuries from "projectile events" (objects being drawn toward the MRI scanner). High-powered magnets in the machine quickly draw items, especially metal, into the machine's chamber.
"The strong magnetic field can attract metallic objects, potentially causing them to become projectiles and injure patients," the FDA's website reads.
The magnetic force "is strong enough to fling a wheelchair across a room," according to the National Institute of Biomedical Imaging and Bioengineering. "Patients should notify their physicians of any form of medical or implant prior to an MR scan."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
21 minutes ago
- Medscape
EMA OKs Oral Treatment for Postnatal Depression
The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has adopted a positive opinion on zuranolone (Zurzuvae, Biogen Netherlands BV), the first oral drug to treat postpartum depression in adults. Marketing authorization was granted in recognition of clinical trial results showing a reduction in postpartum depressive symptoms after 2 weeks' treatment. Zuranolone is a neuroactive steroid that enhances the activity of the neurotransmitter gamma-aminobutyric acid (GABA). It is thought to exert antidepressant effects by enhancing GABAergic inhibition. In a multicenter, randomized, double-blind, placebo-controlled study, zuranolone at a 50 mg dose was given for 14 days to women who met the Diagnostic and Statistical Manual of Mental Disorders criteria for a major depressive episode of postpartum depression and whose symptoms started in the third trimester or within 4 weeks of delivery. Compared with placebo, the active group demonstrated significantly greater symptom improvement on days 3,15 (the primary endpoint), and 45, using the standard 17-item Hamilton rating scale for depression. The FDA approved the drug in August 2023, at which time it was the first oral treatment for postpartum depression, with previous therapies requiring intravenous dosing. It is available in 20 mg, 25 mg, and 30 mg capsules. The most common side effects are somnolence, dizziness, confusion, trouble walking, and sedation. Patients are advised to avoid alcohol and not to drive, operate machinery, or undertake other dangerous activities until at least 12 hours after taking each dose during the 14-day treatment course. There may also be an increased risk of suicidal thoughts and actions in people 24 years of age and younger. Animal studies have suggested a possible risk of teratogenic effects, so women who may become pregnant are advised to use effective contraception during treatment and for 1 week after the final dose, and to alert their healthcare provider should they become pregnant during treatment. The EMA said that detailed recommendations will be described in the summary of product characteristics, which will be published on the EMA website in all official European Union languages after the marketing authorization has been granted by the European Commission. Perinatal Mental Healthcare 'in Its Infancy' In Western countries, postpartum depression is estimated to affect between 10% and 15% of women during the first year after birth , with substantial differences in rates depending on socioeconomic factors such as marital status, educational level, social support, spouse care, violence, gestational age, breast feeding, child mortality, financial difficulties, partnership, life stress, smoking, alcohol intake, and living conditions. Common symptoms include feelings of desperation, sadness, anxiety, irritability, and isolation, as well as nausea, changes in sleep and eating habits, decreased libido, crying spells, mental lability, thoughts of hurting oneself and/or the infant, and suicidal ideation. The condition can wreak havoc on women's mental health as well as that of their partners. It can impair the parental relationship, the mother-child bond, and the emotional and cognitive growth of infants, with potential long-term effects. Postnatal depression may occur alongside post-traumatic stress disorder following stressful or traumatic childbirth experiences . Yet a review published in Frontiers in Psychiatry last year suggested that fewer than half of countries in the World Health Organization (WHO) European region had policies specifically on perinatal mental health, leading its authors to conclude that "perinatal mental health care is in its infancy in most WHO European countries."
Yahoo
2 hours ago
- Yahoo
VCU toxicologist: ‘No vape is safe'
PORTSMOUTH, Va. (WAVY) — The trend of vaping use has picked up speed across the United States, particularly among young adults. But as cool as the smoking devices appear, Virginia Commonwealth University Forensic Toxicologist Dr. Michelle Peace says the e-cigarettes are doing more harm than good. Her candid message — no vape is safe. She has discovered in her research that 95% of all compounds in vape products are not safe to inhale. 'The framework exists for protecting the consumer,' Peace said. 'So enforcement really needs to happen full throttle. Probably just as important is education, as misinformation about vaping is rampant.' It's been her mission to expose the hidden toxic chemicals, as most users are in the dark about what they're actually inhaling. 'The primary compounds that make up a vape liquid are propylene glycol and vegetable glycerin,' she said. 'There are compounds such as ethyl acetate that are used as a flavoring chemical.' Ethyl acetate is also used in fingernail polish remover. 'So there are compounds that are used as industrial solvents to clean equipment and brakes, and the food industry uses them as a solvent for flavoring chemicals. That doesn't mean that they're safe to inhale.' So far, the has authorized 39 tobacco and menthol flavored e-cigarette products, though she says there are too many that are unregulated and without quality testing. 'We have found that the products that are authorized by the Food and Drug Administration do have significantly fewer chemicals in them,' she said, 'where, in an unauthorized product, we might find 15 to 20 different chemicals. And then, in an authorized product, we might find five or six. That's significantly less. But nonetheless, there's still chemicals that can harm people and their tissue.' Users can develop a hacking cough, dried out lung tissue or even worse. 'There are some really interesting studies that are coming out that demonstrate that vaping is changing your DNA,' she said. 'There's an indication that maybe your body is 13 years older than a non vapor. Through a project funded by the Virginia Foundation for Healthy Youth, vapes are confiscated on school campuses in the Commonwealth and sent to VCU for testing. For those indirectly inhaling vapes, there's still a second-hand risk. And the bigger issue, according to Peace, is many people are using vapes to consume other drugs. has reported more than 2,800 vaping hospitalizations nationwide. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
Business Wire
3 hours ago
- Business Wire
Sarepta Therapeutics Acknowledges CHMP Negative Opinion for ELEVIDYS in the European Union
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, acknowledges that the Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the conditional marketing authorization (CMA) for ELEVIDYS (delandistrogene moxeparvovec) in ambulatory individuals ages three to seven years for the treatment of Duchenne muscular dystrophy (DMD). 'While we are disappointed by the CHMP's negative opinion, we understand the urgent need for continued dialogue and collaboration to bring transformative therapies to people with Duchenne who live with a relentless disease that steals their mobility, independence and ultimately life – often by early adulthood," said Louise Rodino-Klapac, Ph.D., president of research & development and technical operations, Sarepta. 'Following the initial FDA approval of ELEVIDYS on June 22, 2023, the therapy has subsequently received regulatory approval in several other countries. In the U.S., we are actively working with the FDA to address recent safety questions. We remain committed to working with regulators to address outstanding questions on safety so that people living with Duchenne have access to this important therapy.' ELEVIDYS is the first and only approved gene therapy targeting the underlying cause of disease that has consistently demonstrated stabilization or slowing of DMD disease progression, with durable effects on functional and biological outcomes and muscle health. While the primary endpoint was not met in EMBARK after one year, ELEVIDYS showed clinically meaningful and statistically significant improvements across important secondary endpoints of functional outcome measures when compared to placebo. Longer term efficacy data were also submitted to EMA, including two-year results from the EMBARK study and three-year pooled efficacy analysis from three other ELEVIDYS studies that showed clinically meaningful improvements across key measures of motor function. One-year data from part one of the EMBARK study were published in Nature Medicine in October 2024, and results from year two were shared at this year's Muscular Dystrophy Association Clinical & Scientific Conference in Dallas. Quantitative muscle MR (magnetic resonance) outcomes from part 1 of EMBARK were published in JAMA Neurology in May 2025. Sarepta is responsible for regulatory approval and commercialization of ELEVIDYS in the U.S., as well as manufacturing. Roche is responsible for regulatory approvals and bringing ELEVIDYS to patients across the rest of the world. Regulatory approval and commercialization of ELEVIDYS in Japan is through Chugai Pharmaceuticals via its alliance with Roche. About ELEVIDYS (delandistrogene moxeparvovec-rokl) ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the DMD gene that result in the lack of dystrophin protein – through the delivery of a transgene that codes for the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle. ELEVIDYS is indicated in U.S. for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age. For patients who are ambulatory and have a confirmed mutation in the DMD gene For patients who are non-ambulatory and have a confirmed mutation in the DMD gene. The DMD indication in non-ambulatory patients is approved under accelerated approval in the U.S. based on expression of ELEVIDYS micro-dystrophin (noted hereafter as 'micro-dystrophin') in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). U.S. IMPORTANT SAFETY INFORMATION CONTRAINDICATION: ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene. WARNINGS AND PRECAUTIONS: Infusion-related Reactions: Infusion-related reactions, including hypersensitivity reactions and anaphylaxis, have occurred during or up to several hours following ELEVIDYS administration. Closely monitor patients during administration and for at least 3 hours after the end of infusion. If symptoms of infusion-related reactions occur, slow, or stop the infusion and give appropriate treatment. Once symptoms resolve, the infusion may be restarted at a lower rate. ELEVIDYS should be administered in a setting where treatment for infusion-related reactions is immediately available. Discontinue infusion for anaphylaxis. Acute Serious Liver Injury: Acute serious liver injury has been observed with ELEVIDYS, and administration may result in elevations of liver enzymes (such as GGT, GLDH, ALT, AST) or total bilirubin, typically seen within 8 weeks. Patients with preexisting liver impairment, chronic hepatic condition, or acute liver disease (e.g., acute hepatic viral infection) may be at higher risk of acute serious liver injury. Postpone ELEVIDYS administration in patients with acute liver disease until resolved or controlled. Prior to ELEVIDYS administration, perform liver enzyme test and monitor liver function (clinical exam, GGT, and total bilirubin) weekly for the first 3 months following ELEVIDYS infusion. Continue monitoring if clinically indicated, until results are unremarkable (normal clinical exam, GGT, and total bilirubin levels return to near baseline levels). Systemic corticosteroid treatment is recommended for patients before and after ELEVIDYS infusion. Adjust corticosteroid regimen when indicated. If acute serious liver injury is suspected, consultation with a specialist is recommended. Immune-mediated Myositis: In clinical trials, immune-mediated myositis has been observed approximately 1 month following ELEVIDYS infusion in patients with deletion mutations involving exon 8 and/or exon 9 in the DMD gene. Symptoms of severe muscle weakness, including dysphagia, dyspnea, and hypophonia, were observed. Limited data are available for ELEVIDYS treatment in patients with mutations in the DMD gene in exons 1 to 17 and/or exons 59 to 71. Patients with deletions in these regions may be at risk for a severe immune-mediated myositis reaction. Advise patients to contact a physician immediately if they experience any unexplained increased muscle pain, tenderness, or weakness, including dysphagia, dyspnea, or hypophonia, as these may be symptoms of myositis. Consider additional immunomodulatory treatment (immunosuppressants [e.g., calcineurin-inhibitor] in addition to corticosteroids) based on patient's clinical presentation and medical history if these symptoms occur. Myocarditis: Acute serious myocarditis and troponin-I elevations have been observed following ELEVIDYS infusion in clinical trials. If a patient experiences myocarditis, those with pre-existing left ventricle ejection fraction (LVEF) impairment may be at higher risk of adverse outcomes. Monitor troponin-I before ELEVIDYS infusion and weekly for the first month following infusion and continue monitoring if clinically indicated. More frequent monitoring may be warranted in the presence of cardiac symptoms, such as chest pain or shortness of breath. Advise patients to contact a physician immediately if they experience cardiac symptoms. Preexisting Immunity against AAVrh74: In AAV-vector based gene therapies, preexisting anti-AAV antibodies may impede transgene expression at desired therapeutic levels. Following treatment with ELEVIDYS, all patients developed anti-AAVrh74 antibodies. Perform baseline testing for presence of anti-AAVrh74 total binding antibodies prior to ELEVIDYS administration. ELEVIDYS administration is not recommended in patients with elevated anti-AAVrh74 total binding antibody titers greater than or equal to 1:400. Adverse Reactions: The most common adverse reactions (incidence ≥5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, and thrombocytopenia. Report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782). For further information, please see the full Prescribing Information. About Sarepta Therapeutics Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (Duchenne) and limb-girdle muscular dystrophies (LGMDs) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit or follow us on LinkedIn, X, Instagram and Facebook. Internet Posting of Information We routinely post information that may be important to investors in the 'For Investors' section of our website at We encourage investors and potential investors to consult our website regularly for important information about us. Forward-Looking Statements This statement contains 'forward-looking statements.' Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as 'will,' 'may,' 'potential' and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to our future operations, research and development programs, discussions with regulators and the prospects for approvals or continued approvals, as applicable, of ELEVIDYS and the potential benefits and risks of ELEVIDYS. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: different methodologies, assumptions and applications we use to assess particular safety or efficacy parameters may yield different statistical results; our products or product candidates may be perceived as insufficiently effective, unsafe or may result in unforeseen adverse events; our products or product candidates may cause undesirable side effects that result in significant negative consequences; the possible impact of regulatory decisions by, and any halts imposed by, regulatory agencies on our business; and those risks identified under the heading 'Risk Factors' in our most recent Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company, which you are encouraged to review. Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained herein. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law. Source: Sarepta Therapeutics, Inc.
